For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Ligand Pharmaceuticals, Inc (NASDAQ: LGND) closed the day trading at $161.71 up 1.09% from the previous closing price of $159.96. In other words, the price has increased by $1.09 from its previous closing price. On the day, 0.15 million shares were traded. LGND stock price reached its highest trading level at $163.34 during the session, while it also had its lowest trading level at $160.05.
Ratios:
For a better understanding of LGND, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 59.54. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.45. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on April 10, 2025, initiated with a Buy rating and assigned the stock a target price of $143.
On October 03, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $135.
On July 30, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $130.RBC Capital Mkts initiated its Outperform rating on July 30, 2024, with a $130 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when KOZARICH JOHN W sold 467 shares for $131.88 per share. The transaction valued at 61,586 led to the insider holds 45,989 shares of the business.
KOZARICH JOHN W bought 467 shares of LGND for $61,177 on Aug 01 ’25. On Jul 10 ’25, another insider, KOZARICH JOHN W, who serves as the Director of the company, sold 934 shares for $125.00 each. As a result, the insider received 116,750 and left with 46,456 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LGND now has a Market Capitalization of 3152455680 and an Enterprise Value of 2929681664. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.89 while its Price-to-Book (P/B) ratio in mrq is 3.79. Its current Enterprise Value per Revenue stands at 15.618 whereas that against EBITDA is 148.504.
Stock Price History:
The Beta on a monthly basis for LGND is 1.00, which has changed by 0.6018821 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, LGND has reached a high of $161.93, while it has fallen to a 52-week low of $93.58. The 50-Day Moving Average of the stock is 18.98%, while the 200-Day Moving Average is calculated to be 37.62%.
Shares Statistics:
Over the past 3-months, LGND traded about 206.95K shares per day on average, while over the past 10 days, LGND traded about 146130 shares per day. A total of 19.41M shares are outstanding, with a floating share count of 19.09M. Insiders hold about 2.58% of the company’s shares, while institutions hold 98.83% stake in the company. Shares short for LGND as of 1755216000 were 1194364 with a Short Ratio of 5.77, compared to 1752537600 on 1233937. Therefore, it implies a Short% of Shares Outstanding of 1194364 and a Short% of Float of 7.4099995000000005.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is $2.02, with high estimates of $2.17 and low estimates of $1.92.
Analysts are recommending an EPS of between $7.05 and $6.74 for the fiscal current year, implying an average EPS of $6.88. EPS for the following year is $7.45, with 6.0 analysts recommending between $8.1 and $6.92.
Revenue Estimates
8 analysts predict $58.71M in revenue for the current quarter. It ranges from a high estimate of $63.7M to a low estimate of $50.15M. As of the current estimate, Ligand Pharmaceuticals, Inc’s year-ago sales were $51.81MFor the next quarter, 8 analysts are estimating revenue of $62.09M. There is a high estimate of $67.86M for the next quarter, whereas the lowest estimate is $55.84M.
A total of 8 analysts have provided revenue estimates for LGND’s current fiscal year. The highest revenue estimate was $220.7M, while the lowest revenue estimate was $205.37M, resulting in an average revenue estimate of $213.75M. In the same quarter a year ago, actual revenue was $167.13MBased on 7 analysts’ estimates, the company’s revenue will be $243.52M in the next fiscal year. The high estimate is $263M and the low estimate is $225.38M.
